Pharmacovigilance Icsr Narrative

Use when a drug-safety case processor, pharmacovigilance scientist, medical reviewer, QPPV / EU-QPPV, US Safety Officer, sponsor safety lead, CRO PV vendor, or marketing authorization holder (MAH) safety operations team needs to draft an ICH E2D / ICH E2B(R3) / EU GVP Module VI–aligned Individual Case Safety Report (ICSR) narrative for a single adverse-event case (spontaneous, solicited, scientific-literature with PubMed ID, clinical-study, or regulatory-authority-transferred). Guides scoped intake of regulatory frame (FDA 21 CFR 314.80 / 600.80, EMA GVP Module VI, PMDA, Health Canada, TGA, NMPA), source and reporter qualification, confirms the four ICH E2D valid-case minimum criteria (identifiable patient, identifiable reporter, suspect product, adverse event/reaction), computes Day 0 and the Day 7 / Day 15 / non-expedited reportability clock, performs PHI-safe intake of patient, history, concomitant medications, and each suspect product with batch / dose / route / dates / action taken, builds the event table with MedDRA LLT and PT proposals, ICH seriousness criteria, dechallenge / rechallenge, outcome, expectedness against the Reference Safety Information (CCDS / IB / USPI / SmPC), and separate reporter and company causality, drafts a chronological Introduction → Body → Conclusion narrative, runs an explicit ICH E2D quality self-check, and produces a DRAFT narrative packet with a targeted follow-up question list and an unsigned safety-physician / QPPV review block — for licensed safety-physician / QPPV review before transmission to FAERS / EudraVigilance / WHO VigiBase / PMDA / Health Canada / TGA. Never assigns the final MedDRA Preferred Term, never finalizes seriousness, expectedness, or company causality, never transmits the ICSR, never closes the case, and never substitutes for the safety physician's or QPPV's medical and regulatory judgment.

by @archlab-space (devasher)·MIT-0